Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vibrating platform help people with stiff lungs breathe easier?

NCT ID NCT07709260

Disease control Sponsor: Istinye University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether adding whole-body vibration to standard pulmonary rehabilitation can improve lung function, exercise capacity, and quality of life in adults aged 40–80 with fibrotic interstitial lung disease. Participants are randomly assigned to either rehab alone or rehab plus vibration sessions twice a week for 8 weeks. The goal is to see if the vibration platform provides extra benefits for breathing and daily function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
whole-body vibration training added to standard pulmonary rehabilitation
What this could lead to
If it works, this could offer a simple, drug-free way to boost exercise capacity and ease breathlessness in people with fibrotic lung disease.
What could go wrong
This is a small, early-stage trial with only 26 participants, so results may not apply widely. The vibration may cause discomfort or fail to provide extra benefit over standard rehab alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Jan 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Ages 40 to 80 years * Diagnosis of fibrotic interstitial lung disease confirmed by a multidisciplinary council (e.g., idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia, sarcoidosis, or other fibrotic patterns) * Receiving stable pharmacological treatment for at least 3 months (e.g., antifibrotic or immunosuppressive therapy) * No acute exacerbation or upper respiratory tract infection within the past 4 weeks * Able to safely participate in pulmonary rehabilitation and whole-body vibration training as determined by clinical evaluation Exclusion Criteria: * Pulmonary hypertension with systolic pulmonary artery pressure \>65 mmHg * Severe cardiovascular disease (e.g., uncontrolled hypertension, congestive heart failure, recent myocardial infarction) * Advanced renal or hepatic failure * Balance disorders preventing safe standing on a vibration platform * Severe musculoskeletal limitations (e.g., advanced arthritis, severe osteoporosis, high fall risk) * Advanced cognitive impairment or dementia * Severe psychiatric disorders (e.g., severe depression or anxiety) * Neurological diseases interfering with participation or test performance * Participation in a pulmonary rehabilitation program during the study or within the past 6 months * Pregnancy or breastfeeding * Uncontrolled metabolic diseases (e.g., advanced diabetes, uncontrolled thyroid dysfunction) * Vestibular system disorders * Active malignancy * Presence of a pacemaker or other contraindicated implanted electronic devices

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung diseases

Contacts and locations

Locations

  • Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi

    Üsküdar, Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.